Response

To the Editor:
We agree that the International Consensus Classifi cation Criteria 1 state that antiphospholipid antibody syndrome can be diagnosed in women with persistent positivity for a lupus anticoagulant (nonspecifi c inhibitor) or moderate to high titer antibodies to IgG or IgM anticardiolipin or b 2 -glycoprotein I, and with recurrent early pregnancy loss, late pregnancy loss, or premature birth because of eclampsia, severe preeclampsia, or placental insuffi ciency. We also state in our article that there is convincing evidence that antiphospholipid antibodies are associated with an increased risk of recurrent early loss and late pregnancy loss. 2 However, as outlined in our article and in a recently published meta-analysis, 3 current data do not support a consistent association between antiphospholipid antibodies and the other pregnancy complications that form the basis of the International Consensus Classifi cation Criteria.
Although there is reasonable evidence to support the use of aspirin and either low-molecular-weight heparin or unfractionated heparin in pregnant women with antiphospholipid antibodies and recurrent early pregnancy loss, similar data to support antithrombotic therapy in women who meet the criteria discussed here on the basis of other placenta-mediated pregnancy complications are absent. 2 , 3 Thrombophilia testing should only be performed when it has the potential to result in a change in patient management. 4 Given the absence of a consistent association between antiphospholipid antibodies and eclampsia, preeclampsia, or placental insuffi ciency, and the lack of data supporting antithrombotic intervention in these patients, as well as those with late loss, we respectfully suggest that it would be inappropriate to recommend testing for the presence of antiphospholipid antibodies in women with pregnancy complications other than recurrent early loss.
